Security key
M40527109
Entera Bio Ltd. - Ordinary shares, par value NIS 0.0000769 per share (ENTX)
CUSIP: M40527109
Q2 2024 13F Holders as of 30 Jun 2024
- Type / Class
- Equity / Ordinary shares, par value NIS 0.0000769 per share
- Shares outstanding
- 45,504,462
- Total 13F shares
- 5,292,989
- Share change
- +1,033,681
- Total reported value
- $9,745,202
- Price per share
- $1.84
- Number of holders
- 14
- Value change
- +$1,916,835
- Number of buys
- 7
- Number of sells
- 7
Report period
Q2 2024
Institutions
14
Top holders
10
ENTX full security history
Newer quarter: Q3 2024
Previous quarter: Q1 2024
Entera Bio Ltd. SEC filings
Entera Bio Ltd. company facts
Broader feeds
Reporting periods
Holder history for CUSIP M40527109
Recent filing periods:
Top shareholders of ENTX - Entera Bio Ltd. - Ordinary shares, par value NIS 0.0000769 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Knoll Capital Management, LLC |
13F
|
Company |
8.5%
|
3,881,879
|
$6,482,738 | — | 31 Mar 2024 | |
| Phillip Schwartz |
3/4/5
|
President of R&D, Director |
—
class O/S missing
|
607,410
|
$601,336 | — | 20 Jan 2022 | |
| UBS Group AG |
13F
|
Company |
0.33%
|
149,869
|
$250,281 | — | 31 Mar 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.16%
|
74,900
|
$125,000 | — | 31 Mar 2024 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.11%
|
51,628
|
$86,219 | — | 31 Mar 2024 | |
| Virtu Financial LLC |
13F
|
Company |
0.05%
|
22,040
|
$37,000 | — | 31 Mar 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.04%
|
19,510
|
$32,582 | — | 31 Mar 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.04%
|
17,597
|
$29,386 | — | 31 Mar 2024 | |
| PNC FINANCIAL SERVICES GROUP, INC. |
13F
|
Company |
0.03%
|
13,000
|
$21,710 | — | 31 Mar 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.03%
|
12,502
|
$20,878 | — | 31 Mar 2024 | |
| HighTower Advisors, LLC |
13F
|
Company |
0.03%
|
11,830
|
$20,000 | — | 31 Mar 2024 | |
| Ramesh Ratan |
3/4/5
|
U.S.based CFO |
—
class O/S missing
|
10,000
|
$9,900 | — | 19 Jan 2022 | |
| Spiros Jamas |
3/4/5
|
Chief Executive Officer |
—
class O/S missing
|
10,000
|
$9,900 | — | 18 Jan 2022 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0.01%
|
3,000
|
$5,000 | — | 31 Mar 2024 | |
| OSAIC HOLDINGS, INC. |
13F
|
Company |
0%
|
1,500
|
$2,505 | — | 31 Mar 2024 | |
| GROUP ONE TRADING LLC |
13F
|
Company |
0%
|
51
|
$85 | — | 31 Mar 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
2
|
$3 | — | 31 Mar 2024 | |
| Roger Garceau |
3/4/5
|
Director |
—
class O/S missing
|
108,333
|
— | — | 01 Jan 2024 | |
| Ron Mayron |
3/4/5
|
Director |
—
class O/S missing
|
108,333
|
— | — | 01 Jan 2024 | |
| Arthur C. Santora II |
3/4/5
|
Chief Medical Officer |
—
class O/S missing
|
35,000
|
— | — | 24 Apr 2023 |
Institutional Holders of Entera Bio Ltd. - Ordinary shares, par value NIS 0.0000769 per share (ENTX) as of Q2 2024
As of 30 Jun 2024,
Entera Bio Ltd. - Ordinary shares, par value NIS 0.0000769 per share (ENTX) was held by
14 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
5,292,989 shares.
The largest 10 holders included
Knoll Capital Management, LLC, Schonfeld Strategic Advisors LLC, Parkman Healthcare Partners LLC, UBS Group AG, RENAISSANCE TECHNOLOGIES LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, GEODE CAPITAL MANAGEMENT, LLC, OSAIC HOLDINGS, INC., PNC Financial Services Group, Inc., and CIBC WORLD MARKET INC..
This page lists
14
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
14
Q2 2024 holders
14
Holder diff
0
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 Value $ | Q2 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.